ARTICLE | Company News
Xencor, MorphoSys in cancer deal
June 29, 2010 1:18 AM UTC
Xencor Inc. (Monrovia, Calif.) granted MorphoSys AG (Xetra:MOR) exclusive, worldwide rights to develop and commercialize XmAb5574. The humanized mAb against CD19 is in Phase I testing to treat chronic...